Adcetris approved by the FDA
Adcetris, formerly known as SGN-35 and one of the more anticipated anti-cancer drugs in recent memory, has received accelerated market approval from the FDA.
Adcetris has been approved for two indications: for patients with Hodgkin's lymphoma who have already received an autologous stem cell transplantation (or for patients who have endured at least two chemotherapy regimens and are not transplant candidates), and for patients with anaplastic large T-cell lymphoma (ALCL) who failed induction therapy. It is the first treatment approved for Hodgkin's since 1977 and the first-ever treatment approved for ALCL.
Developed by Seattle Genetics, Adcetris is a first-in-class therapy known as an antibody drug conjugate; it uses a monoclonal antibody to seek out cells expressing CD30 on their surfaces and delivers an cytotoxic payload, killing the cell.
Resources
Click HERE for more information on Adcetris.
Click HERE for the FDA announcement.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
